Dow Up0.25% Nasdaq Up0.65%

Medgenics, Inc. (MDGN)

5.49 Up 0.21(3.98%) May 27, 4:02PM EDT
ProfileGet Profile for:
Medgenics, Inc.
Building 700
435 Devon Park Drive
Wayne, PA 19087
United States - Map
Phone: 610-254-4201

Index Membership:N/A
Full Time Employees:40

Business Summary 

Medgenics, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. It develops transduced autologous restorative gene therapy (TARGT), a platform to provide protein and peptide therapies to treat a range of chronic diseases. The company’s lead product candidate is MDGN-201, which is an endogenous erythropoietin secretion TARGT that is in the Phase I/II clinical trials for the treatment of end stage renal diseases and other indications, including ß-thalassemia. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Medgenics, Inc.

Corporate Governance 
Medgenics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 2; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Michael F. Cola , 56
Chief Exec. Officer, Pres and Director
Dr. Garry A. Neil M.D., 62
Chief Scientific Officer
Mr. Scott Applebaum , 49
Chief Legal Officer
Dr. Eugene Andrew Bauer M.D., 74
Consultant and Director
Mr. Brian Piper MBA, 44
Chief Financial Officer
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders